AI-driven psychedelic drug discovery

AI-driven psychedelic drug discovery
beyond mental health

Today we speak with Jachym Fibir Co-Founder At April19, they use innovative AI coupled with state-of-the-art computational chemistry to design and develop the next generation of psychedelic-inspired compounds, expanding the utility of psychedelics beyond mental health into neurodegenerative indications and longevity.

The mission:

Classical psychedelics are showing breakthrough therapeutic potential in mental health, but their use is currently limited to certain patients and indications. We deeply respect these compounds and the legacy of indigenous people and research pioneers who discovered the amazing healing power of the psychedelic state.
Standing on the shoulders of these giants, we have identified a unique opportunity to use basic principles of psychedelic action to heal not only mental health, but also to prevent and restore age-related neurodegeneration. Combining together the latest in AI-powered computational chemistry and psychedelic drug design, we are developing a unique class of compounds, which may provide a much-needed answer to the ever-rising threat of cognitive decline and dementia in our constantly aging population.

We have an incredible discussion, that dives deep into the world of psychedelics. We go deep into the objective, subjective, and …….wait for it…..the philosophical nature of it all…imagine that!

I really enjoyed this conversation. It exceeded all of my expectations. If you want to know what the next generation of psychedelics may be then check out the company’s website below. If your an investor NOW is the time!!!!!!!

https://www.april19.ai/#video